Clinomics (CEO Jeong Jong-tae, Kim Byeong-cheol), a company specializing in early cancer diagnosis, announced on the 22nd that it would release an early cancer diagnosis product in the global market in the second half of the year . The company explained that the paid-up capital increase of 44.6 billion won this time was also part of a large-scale strategic investment.
According to Clinomics, it plans to release products for the early detection of colorectal cancer and pancreatic cancer by receiving technology exclusively from Singlera Genomics (Singlera) in the United States. Previously, on April 28, Clinomics signed an agreement with Singlelera, which has patents for early cancer diagnosis technology and research capabilities, to sell biopsy-based liquid cancer early diagnosis products in the global market.
The company will be the first to launch commercial services in the US market for products such as Singlelera’s ColonES (colon and rectal cancer), PDACatch (pancreatic cancer) and Panseer MRD (real-time cancer screening). The service is provided by Clinomics USA, the US branch of Clinomics. In the European market, Clinomics Europe, the European branch of Clinomics, plans to launch cancer screening services such as ColonAiQ (colon cancer) and HepaAiQ (liver cancer).
Byung-Cheol Kim, CEO of Clinomics, said, “This state-of-the-art cancer diagnosis and screening product will exceed the large-scale sales achieved by Clinomics’ corona test service in the United States, Korea, and Europe , and It will act as a stepping stone for continued sales expansion.” The company’s business goal is to exploit and monopolize the early cancer diagnosis market which is worth tens of trillions of money.”
Jeong Jong-tae, CEO of Clinomics, said, “With this legacy of approximately KRW 44.6 billion, we will be ready for the redemption of the existing convertible bonds (CB) that are scheduled,” he said.
Meanwhile, Clinomics plans to launch the ‘Geno’ series, a DTC (Direct To Customer) genetic test product certified by the Ministry of Health and Welfare earlier this year, as a real-life DNA test product in the second half of the year .
